Safety and Preliminary Effectiveness of a Natural, Multi-modal Therapeutic in Postmenopausal Women with Obesity
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Postmenopausal women exhibit increased central obesity due to aging-related alterations in hormones leading to adverse metabolic and biological consequences. The present study aimed to evaluate the safety of a natural, multi-modal therapeutic and observe alterations in metabolic and aging-related outcomes in humans for the first time.
Methods
A non-comparer pilot study was conducted to translate preclinical findings of a glycation-lowering supplement (Alpha-lipoic acid, nicotinamide, thiamine, piperine, pyridoxamine) to postmenopausal women with obesity [n=85; >55 years; BMI=35.0±4.35/30.3–42.8 (Figure 1)]. Qualified participants (n=13) consumed two capsules daily for 6 months. Complete Blood Count [e.g. (Red Cell Distribution Width (RDW%)], Mean Corpuscular Volume (MCH), etc.], depression (Center for Epidemiologic Studies Depression Scale), insulin resistance [Homeostatic Model (HOMA-IR)], fat oxidation [respiratory quotient (RQ)], weight/height, waist circumference (WC), bone mineral density (BMD) by Dual-Energy X-ray Absorptiometry, low (LDL) and high density (HDL) lipoproteins, phenotypic age (PA), follicle stimulating hormone (FSH) caloric intake [(CI)-NIH/NIS/ASA 24-2020 Dietary Assessment], and immediate recall [(IM) BrainCheck] were assessed at baseline and 6-month-follow-up.
Results
No serious adverse events were reported. Six participants reporting mild/moderate adverse events were lost to follow-up. Mixed-effect models (intent-to-treat analysis) compared outcomes prior to (n=13) and following (n=7) the 6-month intervention. RDW% (p=0.009), MCV (p=0004), RQ (p=0.02), WC (p=0.02), HDL (p=0.044), phenotypic age (p=0.037), FSH (0.002), and CI (p=0.01) significantly decreased. Depression (p=0.002), height (p=0.003), BMD (p=0.02) and IM (p=0.04) significantly increased; HOMA-IR and LDL were unchanged.
Conclusions
Preliminary results indicate that a natural, multi-modal therapeutic is safe in postmenopausal women with obesity. Several metabolic and aging-related outcomes improved following the intervention. However, decreased HDL, RDW%, MCV and increased depression warrant further investigation in future randomized-controlled trials. Clinicaltrials.gov # NCT06242535
